Sharecare Inc (NASDAQ: SHCR): Hunting Genuine Value In Market Debris

Currently, there are 353.43M common shares owned by the public and among those 278.44M shares have been available to trade.

The company’s stock has a 5-day price change of -40.86% and -50.41% over the past three months. SHCR shares are trading -49.04% year to date (YTD), with the 12-month market performance down to -64.49% lower. It has a 12-month low price of $0.74 and touched a high of $1.82 over the same period. SHCR has an average intraday trading volume of 1.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -40.68%, -44.86%, and -50.63% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Sharecare Inc (NASDAQ: SHCR) shares accounts for 36.73% of the company’s 353.43M shares outstanding.

It has a market capitalization of $193.97M and a beta (3y monthly) value of 0.26. The earnings-per-share (ttm) stands at -$0.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.37% over the week and 10.61% over the month.

Analysts forecast that Sharecare Inc (SHCR) will achieve an EPS of -$0.05 for the current quarter, -$0.05 for the next quarter and -$0.17 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.1 a year ago. Earnings per share for the fiscal year are expected to decrease by -170.00%, and 0.00% over the next financial year.

Morgan Stanley coverage for the Sharecare Inc (SHCR) stock in a research note released on July 20, 2022 offered a Equal-Weight rating with a price target of $2.50. Goldman was of a view on February 11, 2022 that the stock is Neutral, while Canaccord Genuity gave the stock Buy rating on August 04, 2021, issuing a price target of $11. BTIG Research on their part issued Buy rating on July 28, 2021.

Most Popular

Related Posts